Maxim Reiterates Buy On IsoRay As Its Brain Tumor Seed Shows Positive Results
In a research report published October 7, Maxim Group analyst Jason Kolbert reiterated a Buy rating on IsoRay Inc (NYSE:ISR) with a $5 price target, following the news that a seven year-old Peruvian girl diagnosed with inoperable glioblastoma multiforme (GBM) treated by steriotactic implant of ISR’s Cs-131 seed directly into the tumor in July 2014, has been reported to have 70% tumor reduction.
Kolbert noted, “This study is an important milestone for Isoray as they look to expand their Cs-131 brachytherapy seed franchise beyond prostate cancer. With Cs-131 approved for most solid tumors, adoption is key to market penetration. Management is seeing interest building in the treatment of brain cancers (meningiomas, brain metastases, and glioblastomas), lung cancer (NSCLC), gynecological cancer, prostate cancer, head and neck cancer, and liquid Cesium-131 in the GliaSite Radiation Therapy System, used to treat brain cancers.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 8.4% and a 49.1% success rate. Kolbert has an -26.8% average return when recommending ISR, and is ranked #361 out of 3318 analysts.